MedTrace Logo

A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children

NCT06151587 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 735

Last updated 2023-11-30

No results posted yet for this study

Summary

Efficacy and Safety Study of QLM3004 in Myopic Children

Conditions

  • Myopia

Interventions

DRUG

QLM3004 Concentration 1

Low dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime

DRUG

QLM3004 Concentration 2

Medium dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime

DRUG

QLM3004 Concentration 3

High dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime

OTHER

Placebo

Vehicle

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-20
Primary Completion
2026-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06151587 on ClinicalTrials.gov